Keyphrases
A549 Cells
42%
Antiproliferative Activity
28%
Antitumor Activity
100%
Cell Proliferation
14%
Cell Survival
14%
Cellular Differentiation
14%
Cellular Growth
14%
Clinical Response
14%
Dose Effect
14%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
14%
Gefitinib
100%
Ligand-receptor Binding
14%
Molecular Mechanism
14%
Non-small Cell Lung Cancer (NSCLC)
28%
Peroxisome Proliferator-activated Receptor
42%
Peroxisome Proliferator-activated Receptor Agonists
100%
Phosphatase
14%
Phosphatidylinositol 3-kinase Pathway
14%
Potential Therapeutics
14%
PTEN Expression
100%
Receptor Expression
14%
Rosiglitazone
57%
Tensin Homolog
14%
Biochemistry, Genetics and Molecular Biology
Antineoplastic Activity
100%
Antiproliferative Activity
28%
Cell Growth
14%
Cell Proliferation
14%
Cell Survival
14%
Cellular Differentiation
14%
Epidermal Growth Factor Receptor
14%
Gefitinib
100%
Peroxisome Proliferator-Activated Receptor
42%
Phosphatase
14%
Phosphoinositide 3-Kinase
14%
PPAR Agonist
100%
Rosiglitazone
57%
Tensin
14%
Tyrosine Kinase Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antitumor Activity
100%
Epidermal Growth Factor Receptor
14%
Gefitinib
100%
Non Small Cell Lung Cancer
28%
Peroxisome Proliferator Activated Receptor
42%
Phosphatase
14%
Phosphatidylinositol 3 Kinase
14%
PPAR Agonist
100%
Protein Tyrosine Kinase Inhibitor
14%
Rosiglitazone
57%
Tensin
14%